236 related articles for article (PubMed ID: 6348093)
1. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease.
Falk RJ; Dalmasso AP; Kim Y; Tsai CH; Scheinman JI; Gewurz H; Michael AF
J Clin Invest; 1983 Aug; 72(2):560-73. PubMed ID: 6348093
[TBL] [Abstract][Full Text] [Related]
2. Using polymerized C9 to produce a monoclonal antibody against a neoantigen of the human terminal complement complex.
Kusunoki Y; Takekoshi Y; Nagasawa S
J Pharmacobiodyn; 1990 Jul; 13(7):454-60. PubMed ID: 2290128
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of activation of the human terminal complement pathway by ELISA.
Sanders ME; Schmetz MA; Hammer CH; Frank MM; Joiner KA
J Immunol Methods; 1985 Dec; 85(2):245-56. PubMed ID: 2416846
[TBL] [Abstract][Full Text] [Related]
4. [Terminal complement complex (TTC) levels in plasma and urine from glomerular diseases: enzyme-linked immunosorbent assay (ELISA) using monoclonal antibody against neoantigens of TCC].
Kusunoki Y
Hokkaido Igaku Zasshi; 1990 Jan; 65(1):74-85. PubMed ID: 2328949
[TBL] [Abstract][Full Text] [Related]
5. A biotin-avidin sandwich ELISA for quantification of intact complement component C9. The sera from hereditary C9 deficient individuals completely lack C9.
Takata Y; Moriyama T; Fukumori Y; Yoden A; Shima M; Inai S
J Immunol Methods; 1989 Feb; 117(1):107-13. PubMed ID: 2913155
[TBL] [Abstract][Full Text] [Related]
6. Double immunofluorescence studies of IgA and poly C9 (MAC) in glomeruli from patients with IgA nephropathy.
Eguchi K; Tomino Y; Yagame M; Miyazaki M; Takiura F; Miura M; Suga T; Endoh M; Nomoto Y; Sakai H
Tokai J Exp Clin Med; 1987 Dec; 12(5-6):331-5. PubMed ID: 3334189
[TBL] [Abstract][Full Text] [Related]
7. Heymann antibodies induce complement-dependent injury of rat glomerular visceral epithelial cells.
Camussi G; Salvidio G; Biesecker G; Brentjens J; Andres G
J Immunol; 1987 Nov; 139(9):2906-14. PubMed ID: 3312408
[TBL] [Abstract][Full Text] [Related]
8. Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement.
Zalman LS; Müller-Eberhard HJ
Mol Immunol; 1990 Jun; 27(6):533-7. PubMed ID: 1696352
[TBL] [Abstract][Full Text] [Related]
9. Complement-mediated killing of the Lyme disease spirochete Borrelia burgdorferi. Role of antibody in formation of an effective membrane attack complex.
Kochi SK; Johnson RC; Dalmasso AP
J Immunol; 1991 Jun; 146(11):3964-70. PubMed ID: 2033266
[TBL] [Abstract][Full Text] [Related]
10. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.
Tschopp J; Mollnes TE
Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4223-7. PubMed ID: 2424021
[TBL] [Abstract][Full Text] [Related]
11. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules.
Kontermann R; Deppisch R; Rauterberg EW
Eur J Immunol; 1990 Mar; 20(3):623-8. PubMed ID: 1690659
[TBL] [Abstract][Full Text] [Related]
12. Complement fixation by pemphigus antibody. V. Assembly of the membrane attack complex on cultured human keratinocytes.
Xia P; Jordon RE; Geoghegan WD
J Clin Invest; 1988 Dec; 82(6):1939-47. PubMed ID: 2461964
[TBL] [Abstract][Full Text] [Related]
13. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
14. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
Hetland G; Bungum L
APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
[TBL] [Abstract][Full Text] [Related]
15. A unique epitope exposed in native complement component C9 and hidden in the terminal SC5b-9 complex enables selective detection and quantification of non-activated C9.
Mollnes TE; Tschopp J
J Immunol Methods; 1987 Jun; 100(1-2):215-21. PubMed ID: 2439601
[TBL] [Abstract][Full Text] [Related]
16. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex.
Mollnes TE; Lea T; Frøland SS; Harboe M
Scand J Immunol; 1985 Aug; 22(2):197-202. PubMed ID: 2412280
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.
Kemp PA; Spragg JH; Brown JC; Morgan BP; Gunn CA; Taylor PW
J Clin Lab Immunol; 1992; 37(4):147-62. PubMed ID: 1285067
[TBL] [Abstract][Full Text] [Related]
18. Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition.
Schweinle JE; Nishiyasu M
J Clin Invest; 1992 Apr; 89(4):1198-207. PubMed ID: 1556181
[TBL] [Abstract][Full Text] [Related]
19. Transmembrane channel-formation by five complement proteins.
Müller-Eberhard HJ
Biochem Soc Symp; 1985; 50():235-46. PubMed ID: 2428370
[TBL] [Abstract][Full Text] [Related]
20. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.
Würzner R; Xu H; Franzke A; Schulze M; Peters JH; Götze O
Immunology; 1991 Sep; 74(1):132-8. PubMed ID: 1718850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
